Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis

Sodena and Capital Cell invest €1.600.000 in the biopharmaceutical Leadartis

The entry of funds into leadartis’ shareholding is part of a round of financing closed by the company in recent times. «An action that has endowed it with 1.6 million euros that will advance the development of the first immunotherapy candidate against advanced cancers with high medical need such as lung, colon and breast.»

Leadartishttps://www.webcapitalriesgo.com/leadartis-cierra-una-ronda-de-e16m-a-la-que-acuden-sodena-y-capital-cell

Share with

Start typing and press Enter to search